Analysis of the US Safety Data for Edaravone (Radicava®) From the Third Year After Launch

Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

Koji Abe, Masashi Aoki, Shoji Tsuji et al. · The Lancet Neurology · 2017 · 900 citations

Neurodegenerative Diseases, Amyotrophic Lateral Sclerosis, Neurological Disorder +6

Anaphylaxis in America: The prevalence and characteristics of anaphylaxis in the United States

Robert A. Wood, Carlos A. Camargo, Philip Lieberman et al. · Journal of Allergy and Clinical Immunology · 2013 · 381 citations · Full text

Asthma, Environmental Allergy, Allergy +7

Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients

Koji Abe, Yasuto Itoyama, Gen Sobue et al. · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · 2014 · 348 citations · Full text

Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial

Merit Cudkowicz, Sarah Titus, Marianne Kearney et al. · The Lancet Neurology · 2014 · 231 citations · Full text

Neurodegenerative Diseases, Amyotrophic Lateral Sclerosis, Neurological Disorder +5

Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS)

Sabrina Paganoni, Eric A. Macklin, Alexandra Lee et al. · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · 2014 · 206 citations · Full text

Neurodegenerative Diseases, Disease Diagnosis, Amyotrophic Lateral Sclerosis +15